Premium
AG‐4: a nicotinic agonist endowed with antiamnesic properties
Author(s) -
Ghelardini Carla,
Galeotti Nicoletta,
Mannelli Lorenzo Di Cesare,
Dei Silvia,
Gualtieri Fulvio,
Bartolini Alessandro
Publication year - 2000
Publication title -
drug development research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.582
H-Index - 60
eISSN - 1098-2299
pISSN - 0272-4391
DOI - 10.1002/1098-2299(200011)51:3<191::aid-ddr8>3.0.co;2-k
Subject(s) - mecamylamine , agonist , pharmacology , piracetam , chemistry , physostigmine , amnesia , nicotinic agonist , acetylcholine , medicine , receptor , biochemistry , psychiatry
The effect of the nicotinic agonist AG‐4 on memory processes was evaluated in the mouse passive avoidance test. AG‐4 (100 μg per mouse icv) prevented amnesia induced by scopolamine (1.5 mg kg –1 ip), mecamylamine (20 mg kg –1 ip), and dihydro‐β‐erythroidine (10 μg per mouse icv). In the same experimental conditions, AG‐4 (100 μg per mouse icv) also prevented baclofen (2 mg kg –1 ip), clonidine (0.125 mg kg –1 ip), and diphenhydramine (20 mg kg –1 ip) amnesia in mice. AG‐4 exerted an antiamnesic effect comparable to that produced by nicotine (2 mg kg –1 ip), physostigmine (0.2 mg kg –1 ip), and the nootropic drug piracetam (30 mg kg –1 ip). At the active dose, AG‐4 did not impair mice motor coordination and spontaneous motility as revealed, respectively, by Rota‐rod test and Animex apparatus. Present results evidence the antiamnesic activity of the nicotinic agonist AG‐4 suggesting a potential employment of this compound in the symptomatic treatment of cognitive impairments. Drug Dev. Res. 51:191–196, 2000. © 2001 Wiley‐Liss, Inc.